Fallopian Tube Cancer (FTC)
Fallopian tube cancer (FTC) is a rare and challenging disease that affects the fallopian tubes, an essential component of the female reproductive system. Our commitment to cutting-edge research and development ensures that we remain at the forefront of FTC drug and therapy development, helping to provide superior service and ultimately accelerating R&D for pharmaceutical companies.
Introduction to Fallopian Tube Cancer (FTC)
Fallopian tube cancer (FTC) is a malignant tumor that arises from the cells lining the fallopian tubes. It is a relatively rare form of gynecological cancer, accounting for approximately 0.14-1.8% of all female reproductive tract malignancies. FTC most commonly presents as high-grade serous carcinoma, which is often associated with mutations in the BRCA1 and BRCA2 genes.
Pathogenesis of Fallopian Tube Cancer (FTC)
The exact cause of FTC remains unclear; however, several risk factors have been identified.
- Women with a family history of ovarian, breast, or Lynch syndrome-related cancers are at a higher risk of developing FTC.
- Individuals with BRCA1 and BRCA2 gene mutations have an increased susceptibility to FTC.
- Other potential risk factors include age, obesity, and previous tubal ligation or infertility therapeutic.
Fig.1 Structure and carcinogenesis of fallopian tubes. (Stasenko Marina, et al., 2019)Targets of Fallopian Tube Cancer (FTC) Therapy
DNA Repair Pathways
Mutations in BRCA1 and BRCA2 genes impair DNA repair mechanisms, leading to genomic instability and increased susceptibility to FTC. Targeting these pathways using PARP inhibitors has shown promising results in trials.
Tumor Suppressor Genes
TP53, commonly known as the p53 gene, is frequently mutated in FTC. Targeting p53 signaling pathways may provide potential therapeutic strategies for FTC.
Angiogenesis Pathways
Vascular endothelial growth factor (VEGF) and its receptors are involved in the formation of new blood vessels to support tumor growth. Inhibiting VEGF signaling has demonstrated efficacy in various cancers and may be applicable to FTC as well.
Cell Cycle Regulation
Dysregulation of cell cycle checkpoints is a hallmark of cancer. Targeting proteins involved in cell cycle control, such as cyclin-dependent kinases (CDKs), could potentially disrupt tumor growth in FTC.
Therapy Development of Fallopian Tube Cancer (FTC)
- Chemotherapy
Systemic chemotherapy is an integral part of FTC therapy development. Platinum-based chemotherapy regimens, such as carboplatin and paclitaxel, are commonly used. Poly ADP-ribose polymerase (PARP) inhibitors have also shown promise in patients with BRCA mutations.
- Targeted Therapy
Recent advancements in understanding the molecular mechanisms of FTC have paved the way for targeted therapies. These therapies aim to specifically inhibit the molecular targets involved in the development and progression of FTC, such as BRCA1 and TP53, thereby improving outcomes.
Our Services
Our expert team of researchers and scientists specializes in the identification and development of diagnostics and novel targeted therapies for FTC. Utilizing cutting-edge technologies and robust preclinical models, we strive to advance the field of FTC therapeutics.
Therapy Development Platforms
In addition, we offer customized disease model development services for FTC research, including cell-based models, organoid models, and animal models.
Animal Models of Fallopian Tube Cancer (FTC)
| Cancer Cell Xenografts Models | |
|---|---|
| By working closely with our customers, we select appropriate human FTC cell lines and optimize the transplantation protocols to ensure successful engraftment and tumor growth in mice. Furthermore, we offer customization options to tailor the models to specific research requirements, including the evaluation of novel therapeutic agents or the study of tumor microenvironment interactions. | |
| Environmental Carcinogen Induction Models | |
| Our company offers comprehensive services for the development of environmental carcinogen induction models for FTC research. We utilize well-established protocols to expose animals to specific environmental carcinogens implicated in FTC development, such as talc or hexachlorobenzene. | |
| Optional Species | Mouse, Rat, Monkey, Others |
In addition, our company offers a range of other model development services to support comprehensive FTC research. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Stasenko, Marina, Olga Fillipova, and William P. Tew. "Fallopian tube carcinoma." Journal of Oncology Practice 15.7 (2019): 375-382.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
